Biotech Research, Development and Proprietary Technologies
For more than 30 years, Vancouver Biotech Limited (VBL) has conducted biotech research and development, creating several proprietary technologies. These intellectual properties have been primarily focused on monoclonal antibodies (MABs), including methodologies for the generation of MABs and the development of patented MABs.
These MABs have potential application in the immunodiagnostic and immunotherapy of human diseases and health conditions, including cancer and fertility regulation. VBL’s previous immunodiagnostic work included early pregnancy, ovulation, as well as menopause tests, among others.
The mission of Vancouver Biotech Limited is to develop innovative monoclonal antibodies for immunodiagnostic products and medical devices for the therapeutic treatment of human diseases and health conditions.
VBL was founded in 1988 in Vancouver, Canada by Dr. Gregory Lee. VBL was under a royalty agreement with The University of British Columbia (concluded in 2018), where Dr. Lee was a tenured professor in the Faculty of Medicine, Department of Obstetrics & Gynaecology for 31 years. Dr. Lee holds a B.Sc. in Chemistry/Physical Biochemistry from National Taiwan University, Taiwan and a M.Sc. and Ph.D. in Chemistry from the California Institute of Technology, USA.



Anti-human Cardiac Troponin I (TPC110)


Immunotherapeutic Applications of RP215 MAB for Cancer Treatment


Immunodiagnostic Applications of CA215 as Pan-Cancer Biomarker for Cancer Monitoring


Immunotherapeutic Applications of GHR106 MABs for Cancer Treatment


GHR106 MAB as Bioequivalent Drugs for Fertility Regulation & Control

President & Founder

Business Manager
9121 Shaughnessy Street
                        
                        Vancouver, BC, Canada
                        
                        V6P 6R9
©2025 - Vancouver Biotech Limited. All Rights Reserved.